Stanford biotech spinout snares $100M round on path toward IPO
July 02, 2020 at 17:16 PM EDT
The South San Francisco company has raised more than $250 million since its 2013 launch targeting a protein that could hold the key to treating neurodegenerative, autoimmune and eye diseases.
